[go: up one dir, main page]

BR9911397A - Utilização de partìculas de proteìnas invólucro de hcv para vacinação - Google Patents

Utilização de partìculas de proteìnas invólucro de hcv para vacinação

Info

Publication number
BR9911397A
BR9911397A BR9911397-0A BR9911397A BR9911397A BR 9911397 A BR9911397 A BR 9911397A BR 9911397 A BR9911397 A BR 9911397A BR 9911397 A BR9911397 A BR 9911397A
Authority
BR
Brazil
Prior art keywords
hcv
proteins
vaccination
particles
envelope protein
Prior art date
Application number
BR9911397-0A
Other languages
English (en)
Inventor
Erik Depla
Geert Maertens
Alfons Bosman
Frans Van Wijnendaele
Original Assignee
Innogenetics Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26152268&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9911397(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Innogenetics Nv filed Critical Innogenetics Nv
Publication of BR9911397A publication Critical patent/BR9911397A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/826—Viruses

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

"UTILIZAçãO DE PARTìCULAS DE PROTEìNAS INVóLUCRO DE HCV PARA VACINAçãO". A presente invenção baseia-se na verificação de que as proteínas invólucro de HCV induzem uma resposta imune benéfica em chimpanzés cronicamente infectados por HCV. A imunização pode ser realizada, preferivelmente, usando proteínas invólucro de HCV na forma de partículas que são produzidas em uma maneira auxiliada por detergente. As proteínas invólucro quando apresentadas como tal aos veículos de HCV crónico, são altamente imunogênicas e estimulam a resposta imune celular e humoral.
BR9911397-0A 1998-06-24 1999-06-23 Utilização de partìculas de proteìnas invólucro de hcv para vacinação BR9911397A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP98870142 1998-06-24
EP99870033 1999-02-22
PCT/EP1999/004342 WO1999067285A1 (en) 1998-06-24 1999-06-23 Particles of hcv envelope proteins: use for vaccination

Publications (1)

Publication Number Publication Date
BR9911397A true BR9911397A (pt) 2002-01-15

Family

ID=26152268

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9911397-0A BR9911397A (pt) 1998-06-24 1999-06-23 Utilização de partìculas de proteìnas invólucro de hcv para vacinação

Country Status (21)

Country Link
US (3) US6635257B1 (pt)
EP (2) EP1090033B2 (pt)
JP (1) JP2002518037A (pt)
KR (1) KR100559096B1 (pt)
CN (1) CN1313864A (pt)
AT (1) ATE286067T1 (pt)
AU (1) AU765940B2 (pt)
BR (1) BR9911397A (pt)
CA (1) CA2330526A1 (pt)
DE (1) DE69922958T3 (pt)
DK (1) DK1090033T4 (pt)
ES (1) ES2237115T5 (pt)
HK (1) HK1037639A1 (pt)
HU (1) HU227275B1 (pt)
IL (2) IL140217A0 (pt)
NZ (2) NZ528952A (pt)
PL (1) PL201679B1 (pt)
PT (1) PT1090033E (pt)
RU (1) RU2247729C2 (pt)
TR (1) TR200003843T2 (pt)
WO (1) WO1999067285A1 (pt)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040185061A1 (en) * 1994-07-29 2004-09-23 Innogenetics N.V. Redox reversible HCV proteins with native-like conformation
US7108855B2 (en) 1998-06-24 2006-09-19 Innogenetics N.V. Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
ATE286067T1 (de) * 1998-06-24 2005-01-15 Innogenetics Nv Hcv hüllproteine partikel : verwendung für therapeutische impfung
US6534064B1 (en) * 1999-10-13 2003-03-18 Chiron Corporation Stabilized protein particles for inducing cellular immune responses
WO2001093905A1 (en) * 2000-06-08 2001-12-13 Intercell Biomedizinische Forschungs- Und Entwicklungs Ag Immunostimulatory oligodeoxynucleotides
EP1315511A4 (en) * 2000-09-08 2005-10-19 Gryphon Therapeutics Inc SYNTHESIS PROTEINS STIMULATING ERYTHROPOYSIS
EP1326625A4 (en) * 2000-09-13 2005-05-04 Hawaii Biotech Inc IMMUNOGENIC COMPOSITION OF HEPATITIS C AND METHODS OF USING THE SAME
US7101561B2 (en) * 2000-12-01 2006-09-05 Innogenetics N.V. Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
WO2002086101A2 (en) 2001-04-24 2002-10-31 Innogenetics N.V. Core-glycosylated hcv envelope proteins
GB0114629D0 (en) * 2001-06-15 2001-08-08 Pfizer Ltd Method
CN1622828A (zh) * 2001-12-18 2005-06-01 基因创新有限公司 用于诊断和治疗用途的纯化的丙型肝炎病毒外被蛋白
US20040126395A1 (en) * 2001-12-18 2004-07-01 Geert Maertens Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
FR2839722A1 (fr) 2002-05-17 2003-11-21 Bio Merieux Nouvelles compositions peptidiques et leur utilisation notamment dans la preparation de compositions pharmaceutiques actives contre le virus de l'hepatite c
JP2004085528A (ja) * 2002-07-05 2004-03-18 Kansai Tlo Kk 拡散定数変化による蛋白質の会合検出方法及び装置
EP1553963A4 (en) * 2002-09-24 2006-05-03 Burnham Inst NEW MEANS FOR MODULATING EPH RECEPTOR ACTIVITY
EP1852441B1 (en) * 2002-09-24 2012-03-28 The Burnham Institute Agents that modulate EPH receptor activity
EP1481985A1 (en) * 2003-05-28 2004-12-01 Innogenetics N.V. Modified hepatitis C virus (HCV) NS3 for medical treatment
EP1561470A1 (en) * 2003-06-20 2005-08-10 Innogenetics N.V. HCV vaccines comprising the envelope-1 (E1) protein or the corresponding DNA and at least one antiviral agent
CN1889963A (zh) * 2003-10-10 2007-01-03 宝德杰克特疫苗有限公司 方法
WO2006070028A1 (es) * 2004-12-23 2006-07-06 Berthet Francois Xavier Composiciones y procedimientos para detectar infección patógena
GB0500020D0 (en) 2005-01-04 2005-02-09 Novartis Ag Organic compounds
EP1574517A1 (en) * 2004-03-09 2005-09-14 Innogenetics N.V. HCV E1 comprising specific disulfide bridges
WO2006033012A2 (en) * 2004-09-24 2006-03-30 Pfizer Limited Method of screening for modulators of hepatitis c virus infection
DE102004057111A1 (de) 2004-11-26 2006-06-01 Niles-Simmons Industrieanlagen Gmbh Verfahren zum Zwischenbearbeiten von Wellen
KR20070118230A (ko) 2005-01-27 2007-12-14 더 번햄 인스티튜트 Ｅｐｈｂ 수용체-결합 펩티드
WO2007041432A2 (en) * 2005-09-30 2007-04-12 Novartis Vaccines And Diagnostics, Inc. Cross-neutralization of hcv with recombinant proteins
EP2004684A4 (en) * 2006-03-22 2009-05-06 Genimmune N V THE HEPATITIS C-VIRUS NEUTRALIZING ANTIBODIES
CA2722423A1 (en) * 2008-04-22 2009-10-29 Rutgers, The State University Hcv e2 construct compositions and methods
US9758794B2 (en) 2008-04-22 2017-09-12 Rutgers, The State University Of New Jersey HCV E2 construct compositions and methods
WO2010052214A2 (en) * 2008-11-05 2010-05-14 Glaxosmithkline Biologicals S.A. Novel method
BR112013032675A2 (pt) * 2011-06-19 2017-08-08 Vaxine Pty Ltd composição adjuvante de vacina compreendendo partículas de inulina
JP6567824B2 (ja) * 2011-10-12 2019-08-28 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア ヒトパピローマウイルスのワクチンおよびその使用方法
RU2510998C2 (ru) * 2012-08-01 2014-04-10 Николай Николаевич Грановский ВАКЦИНА НА ОСНОВЕ ВИРУСОПОДОБНЫХ ЧАСТИЦ, СОДЕРЖАЩИХ ВСЕ СТРУКТУРНЫЕ АНТИГЕНЫ ВИРУСА ГЕПАТИТА С, И СПОСОБ ЕЕ ПОЛУЧЕНИЯ В ДРОЖЖАХ Hansenula polymorpha
JP6517779B2 (ja) 2013-03-12 2019-05-22 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア ヒトパピローマウイルスの改良型ワクチンおよびその使用方法
US11324818B2 (en) 2016-09-21 2022-05-10 The Governors Of The University Of Alberta Hepatitis c virus immunogenic compositions and methods of use thereof
JP6795468B2 (ja) * 2017-07-14 2020-12-02 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア ヒトパピローマウイルスのワクチンおよびその使用方法
JP7075130B2 (ja) * 2019-10-25 2022-05-25 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア ヒトパピローマウイルスのワクチンおよびその使用方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4395395A (en) * 1979-05-21 1983-07-26 The United States Of America As Represented By The Department Of Health And Human Services Detection of non-A, non-B hepatitis associated antigen
US6274148B1 (en) * 1990-11-08 2001-08-14 Chiron Corporation Hepatitis C virus asialoglycoproteins
EP0992580B1 (en) * 1993-11-04 2005-03-09 Innogenetics N.V. Immunodominant human T-cell epitopes of Hepatitis C virus
SG71728A1 (en) * 1994-07-29 2000-04-18 Innogenetics Nv Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use
AU702436B2 (en) * 1994-10-21 1999-02-18 Innogenetics N.V. New sequences of hepatitis C virus genotypes and their use as prophylactic, therapeutic and diagnostic agents
CA2269097C (en) 1996-11-08 2007-01-09 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Synthesis and purification of hepatitis c virus-like particles
EP1071955B2 (en) * 1998-04-17 2009-02-18 N.V. Innogenetics S.A. Improved immunodiagnostic assays using reducing agents
ATE286067T1 (de) * 1998-06-24 2005-01-15 Innogenetics Nv Hcv hüllproteine partikel : verwendung für therapeutische impfung

Also Published As

Publication number Publication date
AU4615299A (en) 2000-01-10
DK1090033T3 (da) 2005-04-25
DE69922958T2 (de) 2006-03-30
JP2002518037A (ja) 2002-06-25
PT1090033E (pt) 2005-05-31
US20060275323A1 (en) 2006-12-07
PL201679B1 (pl) 2009-04-30
EP1090033B2 (en) 2007-12-19
EP1090033A1 (en) 2001-04-11
CA2330526A1 (en) 1999-12-29
ES2237115T3 (es) 2005-07-16
ES2237115T5 (es) 2008-05-16
DE69922958T3 (de) 2008-06-26
EP1090033B1 (en) 2004-12-29
AU765940B2 (en) 2003-10-02
HK1037639A1 (en) 2002-02-15
ATE286067T1 (de) 2005-01-15
KR100559096B1 (ko) 2006-03-15
TR200003843T2 (tr) 2001-06-21
HUP0102478A3 (en) 2004-10-28
NZ528952A (en) 2004-09-24
US20030202987A1 (en) 2003-10-30
HUP0102478A2 (hu) 2001-10-28
CN1313864A (zh) 2001-09-19
IL140217A0 (en) 2002-02-10
WO1999067285A1 (en) 1999-12-29
DE69922958D1 (de) 2005-02-03
PL345018A1 (en) 2001-11-19
IL140217A (en) 2009-09-22
HU227275B1 (en) 2011-01-28
NZ508797A (en) 2004-02-27
US6635257B1 (en) 2003-10-21
DK1090033T4 (da) 2008-03-31
KR20010053181A (ko) 2001-06-25
RU2247729C2 (ru) 2005-03-10
EP1555270A1 (en) 2005-07-20

Similar Documents

Publication Publication Date Title
BR9911397A (pt) Utilização de partìculas de proteìnas invólucro de hcv para vacinação
HUP0004327A1 (en) Fusion proteins containing human papilloma virus (hpv) proteins and immunological fusion partner with t-helper epitopes to the hpv antigen, as well as vaccine formulations for treatment and/or profilaxis of hpv induced lesions
ES2059565T3 (es) Virus mva de la vacuna, recombinante.
EA200100425A1 (ru) Новые способы терапевтической вакцинации
ATE320493T1 (de) Modifizierung des hepatitis b kernantigens
BR9814487A (pt) "vacina"
AR018603A1 (es) Un peptido, util para el tratamiento y/o profilaxis de la enfermedad de alzheimer y el sindrome de down, las composiciones farmaceuticas y vacunas que locontienen, el uso de dicho peptido para la preparacion de las composiciones farmaceuticas, una secuencia de aislado de adn, un plasmido o vector vi
CO5700784A2 (es) Polipeptidos de virus de papiloma humano y composiciones in- munogenas
NZ319786A (en) HCV NS3 protein fragments with helicase activity and improved solubility
IL90035A (en) Synthetic multimeric hepatitis b virus vaccine including both t cell and b cell determinants
BR0312474A (pt) Partìcula viral adjuvante
DK0909323T3 (da) Helicobacter pylori-bakterioferritin
ATE134874T1 (de) Synoviale phospholipasen
FI923020A0 (fi) Inte a inte b-sekvenser.
AU7546500A (en) Designing immunogens
ATE403007T1 (de) Rekombinantes mva mit der fähigkeit zur expression von hcv struktur-antigenen
BRPI0409321A (pt) antìgeno hìbrido, competição e método para induzir uma resposta imune para um agente infeccioso ou antìgeno de tumor, método para tratar uma doença infecciosa ou cáncer, e, peptìdeo
AU2002317474A1 (en) Human recombinant antibody against the hepatitis c (hcv) non structural ns3 protein, nucleic acid and uses thereof
MXPA05004849A (es) Novedosas composiciones de multiples peptidos antigenicos relacionados con inhibina, que mejoran el desempeno de produccion avicola.
TR200002611T2 (tr) Beta-lipotropin ve kullanımları
DE602004019141D1 (de) Isoleucyl-valyl-threonyl-asparaginyl-threonyl-threonin (ivtntt) enthaltende biologisch wirksame peptide
DE69827880D1 (de) Iga1-protease fragment als trägerpeptid
KR970010787A (ko) B형 간염 바이러스 표면항원과 c형 간염 바이러스 외피 단백질의 융합 단백질 및 이를 포함하는 혼합 백신
BR9810046A (pt) Sequência de nucleotìdeos, vetor de expressão, célula hospedeira, proteìna de esperma de mamìfero, proteìna de esperma recombinante, proteìna 4, 1 e/ou 6,7 de esperma, composição farmacêutica, e, vacina contraceptiva
PT96223A (pt) Processo para a preparacao de um agente viral responsavel pela hepatite nao-a bnao-b de pos-transfusao

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O, 13, 24 E 25 DA LPI.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.